Biofrontera Inc. announced the completion and database lock of its Phase 1 pharmacokinetics $(PK)$ study evaluating Ameluz® topical gel for the treatment of mild to moderate actinic keratoses (AKs) on the neck, trunk, and extremities. The PK data, together with previously announced positive Phase 3 efficacy results, are intended to support a supplemental New Drug Application for label expansion in the U.S., with submission expected in the third quarter of 2026. Study results have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655744-en) on February 17, 2026, and is solely responsible for the information contained therein.